Published in J Alzheimers Dis on July 25, 2017
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement (2013) 7.69
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage (2008) 3.74
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 3.69
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology (2005) 3.55
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (2010) 3.16
Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc (2005) 3.07
Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology (2003) 2.85
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol (2009) 2.79
One-year brain atrophy evident in healthy aging. J Neurosci (2009) 2.61
Trajectories of brain loss in aging and the development of cognitive impairment. Neurology (2007) 2.60
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage (2012) 2.11
A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry (2006) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain (2009) 2.05
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology (2007) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology (2009) 1.94
MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry (2005) 1.93
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement (2016) 1.93
Non-stationarity in the "resting brain's" modular architecture. PLoS One (2012) 1.90
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci (2001) 1.84
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology (2000) 1.74
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology (2013) 1.74
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology (2008) 1.71
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry (2005) 1.71
Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol (2012) 1.71
Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology (2005) 1.70
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One (2012) 1.64
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol (2013) 1.63
Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression. J Neurol (2008) 1.60
High-dimensional pattern regression using machine learning: from medical images to continuous clinical variables. Neuroimage (2010) 1.60
Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol (2014) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation (2010) 1.57
Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology (2007) 1.57
Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology (2012) 1.56
Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology (2010) 1.56
Comparison of phantom and registration scaling corrections using the ADNI cohort. Neuroimage (2009) 1.53
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr (2013) 1.53
Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol (2008) 1.51
Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol (2015) 1.50
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A (2013) 1.46
Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage (2010) 1.46
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol (2011) 1.40
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp (2010) 1.40
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage (2007) 1.37
Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr (2012) 1.36
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain (2014) 1.36
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology (2007) 1.33
Vascular burden and Alzheimer disease pathologic progression. Neurology (2012) 1.31
A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. Neuroimage (2012) 1.31
Natural history of cognitive decline in the old old. Neurology (2003) 1.31
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol (2016) 1.30
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 1.30
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry (2010) 1.29
Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology (2013) 1.29
Coevolution of white matter hyperintensities and cognition in the elderly. Neurology (2012) 1.28
Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain (2010) 1.22
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol (2013) 1.22
A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis (2011) 1.20
Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. J R Soc Interface (2016) 0.78
Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. Eur J Epidemiol (2017) 0.75